iiinova — where your digital self keeps evolving

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 30/09/2026

The FDA has approved the drug belzutifan in combination with lenvatinib for patients with a type of #kidneycancer called clear cell renal cell carcinoma (ccRCC). The approval was based on a clinical trial led by Dr. Robert Motzer, a genitourinary medical oncologist at MSK. bit.ly/4hiaiJO

021

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 28/09/2026

New research from MSK shows how a metabolite boosts immune cells against cancer; adds to the understanding of how colorectal cancer spreads; and more: bit.ly/4z2sJbt

031

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 29/09/2026

At #ASTRO26, MSK researchers presented studies on organ preservation and circulating tumor DNA (ctDNA) monitoring in rectal and anal cancers. Their work examines how treatment and follow-up care could be tailored to each patient. Read about the studies and their findings: bit.ly/4hsBnsA

012

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 29/09/2026

Tomorrow at #ASTRO26: MSK radiation oncologist Dr. Kevin Boehm will present research using pathology images and clinical tumor sequencing from more than 60,000 patients to model cancer subtypes and molecular features. 🗓️ Wednesday, September 30 | 8:20 a.m. ET Learn more: bit.ly/4ACpx7M

022

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 30/09/2026

Coming up at #ASTRO26: MSK radiation oncologist Dr. Brandon Imber will present research on bridging radiotherapy and systemic inflammation before CAR T-cell therapy for B-cell lymphomas. 🗓️ Wednesday, September 30 | 9:15 a.m. ET Learn more: bit.ly/3VCyz4K

021

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 27/09/2026

Coming up at #ASTRO26: MSK radiation oncologist Dr. Nancy Lee will present a pooled analysis of trials studying FMISO PET-guided, lower-dose radiation for HPV-positive oropharyngeal cancer. 🗓️ Sunday, September 27 | 3 p.m. ET Learn more: bit.ly/4yYOmcE

121

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 28/09/2026

Coming up at #ASTRO26: MSK's Dr. George Naoum will present a validated tool that predicts the risk of invasive breast cancer recurrence for patients with N1mic disease treated with or without nodal radiotherapy. 🗓️ Monday, September 28 | 8:30 a.m. ET Learn more: bit.ly/4hsThvo

011

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 28/09/2026

Today at #ASTRO26: MSK radiation oncologist Dr. Alexander Goglia will present five-year outcomes from a trial of MR-guided SBRT with a focal DIL boost for intermediate-risk prostate cancer. 🗓️ Monday, September 28 | 3:10 p.m. ET Learn more: bit.ly/47lXHPT

022

MSK Department of Medicine @mskdeptofmed.bsky.social · 25/09/2026

Starting soon at #IMS26: Dr. Juan-Jose Garces will present a new method to identify patients with GPRC5D-negative multiple myeloma with t(11;14) translocation, helping guide clinical decision making. 🗓️ Friday, September 25 🕐 12 p.m. BT (7 a.m. ET) @mskcancercenter.bsky.social

Dr. Juan-Jose Garces smiles at the camera.

000

MSK Department of Medicine @mskdeptofmed.bsky.social · 24/09/2026

Starting at 11 a.m. BT at #IMS26 in Glasgow: Dr. Theresia Akhlaghi will present new findings that point to CD4-dominant, T-helper-skewed T cell state as a contributor to movement and neurocognitive toxicity after BCMA-directed CAR T therapy in multiple myeloma. @mskcancercenter.bsky.social

Myeloma expert Dr. Theresia Akhlaghi smiles at the camera.

000

MSK Department of Medicine @mskdeptofmed.bsky.social · 23/09/2026

Coming up at #IMS26: Dr. Neha Korde will present phase 1/2 trial results on alternating daratumumab-RVD and teclistamab-RVD in transplant-eligible, standard-risk newly diagnosed multiple myeloma. 🗓️ Wednesday, September 23 🕛 12 p.m. BT (7 a.m. ET) @mskcancercenter.bsky.social

Myeloma specialist Dr. Neha Korde smiles at the camera in a white coat.

010

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 21/09/2026

The approval is based on results from the EMBER-3 clinical trial. MSK breast medical oncologist Dr. Komal Jhaveri was International Study Chair and member of the steering committee for the trial. Learn more: www.mskcc.org/news/imlunes...

021

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 21/09/2026

🚨 The FDA has approved imlunestrant (Inluriyo™) in combination with abemaciclib (Verzenio®) for patients with ER-positive, HER2-negative advanced #breastcancer with an ESR1 gene mutation who were previously treated with hormone therapy.

121

MSK Department of Medicine @mskdeptofmed.bsky.social · 14/09/2026

At #WCLC26, @mskcancercenter.bsky.social lung cancer expert Adam Schoenfeld will share trial results of an investigational therapy combination for advanced/metastatic small cell or non-small cell lung cancer. September 15, 2026, at 12:42 p.m. KST Presentation details: bit.ly/4xpyONZ

MSK Lung cancer expert Adam Schoenfeld smiles at the camera against a green background.

000

MSK Department of Medicine @mskdeptofmed.bsky.social · 13/09/2026

Don't miss this #WCLC26 Presidential Symposium: @mskcancercenter.bsky.social lung cancer expert Dr. Alexander Drilon will present efficacy & safety data on a treatment for TKI-naive advanced ROS1+ non-small cell lung cancer. September 14, 2026, at 9:38 a.m. KST Details here: bit.ly/4xKYjtW

MSK lung cancer expert Dr. Alexander Drilon smiles at the camera.

000

MSK Department of Medicine @mskdeptofmed.bsky.social · 07/09/2026

🚨 Coming up September 18–19, 2026: Attend the NCCN 2026 Annual Congress on Hematologic Malignancies in person or virtually. The event is chaired by MSK lymphoma specialist Dr. Andrew Zelenetz. CE/MOC credit available. Register now: bit.ly/Hem2026 #NCCNCongress @mskcancercenter.bsky.social

Image showing an advertisement for the NCCN 2026 Annual Congress: Hematologic Malignancies. It is scheduled for September 18-19, 2026, at the New York Marriott Marquis, New York, NY, and virtually.

001

MSK Department of Medicine @mskdeptofmed.bsky.social · 04/09/2026

Don't miss the Third Annual Kyle Barlogie Plasma Cell Disorders Symposium from October 9–12, 2026. Register by September 11 to get the early-bird reduced rate! Register here: cvent.me/7lkMy2 @mskcancercenter.bsky.social @mayocliniccancer.bsky.social

Text overlay on graphic announces the "3rd Annual Kyle Barlogie 2026 Plasma Cell Disorders Symposium" with details: "Register Today! October 9 - 10, 2026, In-person, New York, NY.

011

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 31/08/2026

What if a blood test could detect lymphoma more precisely than an imaging scan? MSK's Dr. Mark Roschewski is studying how blood-based tests for circulating tumor DNA may help guide treatment decisions and determine whether cancer remains after therapy. Learn more: bit.ly/4zZOwlx

0106

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 03/09/2026

🚨 New research in @nejm.org: In a phase 1/2 trial led by MSK’s @kcarbourmd.bsky.social, more than 30% of patients with previously treated metastatic lung cancer responded to daraxonrasib. The targeted therapy could expand treatment options for people with lung cancer. More: bit.ly/4gACirQ

011

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 21/08/2026

New clinical trial data led by MSK’s Dr. Robert Motzer supports a novel combination therapy for patients with advanced clear cell renal cell carcinoma whose disease progressed after immunotherapy. The findings point to a potential new treatment option. Learn more: bit.ly/45HXSUT

021

Reposted by MSK Department of Medicine

Stanford Department of Medicine @stanforddeptmed.bsky.social · 24/08/2026

New on #FutureOfMedicine with #StanDOM's @euanashley.bsky.social: @mskcancercenter.bsky.social Chief Scientific Officer Ross Levine discusses how a microscopic change in a single gene (JAK2) helped reshape how doctors understand & treat a group of #BloodCancers. bit.ly/4hGuq93

032

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 26/08/2026

The FDA has approved #daraxonrasib for certain patients with metastatic pancreatic cancer. MSK’s Dr. Eileen O'Reilly led the phase 3 trial showing it doubled median survival compared with chemotherapy. Learn more about the approval and what it could mean for patients: bit.ly/4zM7xYv

052

Reposted by MSK Department of Medicine

Karuna Ganesh @karunamdphd.bsky.social · 05/08/2026

1/ Delighted to share our paper out today in Nature: ZFP36L2 orchestrates stress-adaptive plasticity in regeneration and cancer. We found the switch that lets differentiated cells rewind into stem cells — in gut repair, and in metastasis. 🧵 doi.org/10.1038/s415...

doi.org

ZFP36L2 orchestrates stress-adaptive plasticity in regeneration and cancer - Nature

The RNA-binding protein ZFP36L2 mediates stress-adaptive plasticity in intestinal regeneration and colorectal cancer metastasis.

33210

Reposted by MSK Department of Medicine

Benjamin D. Greenbaum @bengrbm.bsky.social · 04/08/2026

We are hiring fellows for a pilot initiative at @mskcancercenter.bsky.social – The Theory Group. The Group is centered around tumor-immune interactions and, post-AI, theoretical approaches that can unlock fundamental questions with translational impact. msk.wd108.myworkdayjobs.com/MSKCC_Career...

msk.wd108.myworkdayjobs.com

Research Scholar

About Us: The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert ca...

083

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 06/08/2026

Inherited #BRCA1 and #BRCA2 mutations may affect how breast tumors respond to treatment, according to a study of more than 5,800 patients. MSK's Dr. Pedram Razavi discussed the findings with @targetedonc.bsky.social and how they could inform future treatment strategies: bit.ly/4hMRBym

021

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 10/08/2026

The FDA has expanded approval of Pluvicto® (¹⁷⁷Lu-PSMA-617) as an initial treatment for people with metastatic prostate cancer whose tumors are positive for the PSMA protein. The approval is based on results from the phase 3 PSMAddition trial, led in the U.S. by MSK's Dr. Michael Morris.

mskcc.org

FDA Expands Approval of Pluvicto® for Metastatic Prostate Cancer: Targets a Protein Called PSMA | Memorial Sloan Kettering Cancer Center

Learn more about a new radiopharmaceutical treatment for prostate cancer approved by the FDA for more patients.

011

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 30/07/2026

The FDA has approved zenocutuzumab for adults with advanced, inoperable, or metastatic cholangiocarcinoma driven by an NRG1 gene fusion. The approval is based on a trial led by MSK’s Dr. Alison Schram giving patients with limited treatment options a new choice. Learn more: bit.ly/4fGFXTf

041

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 30/07/2026

The FDA has approved zidesamtinib for advanced ROS1-positive non-small cell #lungcancer that stopped responding to other #ROS1 drugs. MSK thoracic medical oncologist Dr. Alexander Drilon led the clinical trial. Learn more: bit.ly/4q7Bluh

021

MSK Department of Medicine @mskdeptofmed.bsky.social · 24/07/2026

Join leading experts at the Third Annual Plasma Cell Disorders Symposium to explore the latest advances in #Immunotherapy, CAR T cell therapies, bispecific antibodies, and more. @mskcancercenter.bsky.social @mayocliniccancer.bsky.social Register here: cvent.me/7lkMy2

Skyline of New York City with text overlay: "3rd Annual Kyle Barlogie 2026 Plasma Cell Disorders Symposium." Additional text: "REGISTER TODAY! October 9 - 10, 2026 | IN-PERSON | New York, NY.

010

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 30/06/2026

New research from MSK decodes how mesothelioma evades #immunotherapy; shows why a common kidney cancer treatment combination falls short; and supports a free, open-source #AI-driven drug discovery initiative. Learn more: bit.ly/4uZZDHb

021

Reposted by MSK Department of Medicine

Blood Journals Portfolio @bloodjournals.hematology.org · 01/07/2026

We're thrilled to welcome a new Associate Editor to Blood today! Dr. Omar Abdel-Wahab is the Evnin Family Chair of Molecular Pharmacology at @mskcancercenter.bsky.social where he also serves as Chair of the Molecular Pharmacology Program in the Sloan Kettering Institute. #NewEditor

042

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 09/07/2026

The FDA has granted full approval for an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. More about the clinical trials resulting in the drug’s approval, led by MSK's Dr. Sandra D’Angelo: bit.ly/4eVcTZ4

032

Reposted by MSK Department of Medicine

STEMCELL Science News @stemcellsciencenews.com · 10/07/2026

Novel #immunotherapy approaches such as T cell-engager therapies, CD40 agonists, and HSV-TK gene therapy have shown early promise for the treatment of #ProstateCancer. Read the review from Drs. Dallos, Gaffney, and @mskcancercenter.bsky.social collaborators. 📖 🔗 go.nature.com/4vRA5x7

022

MSK Department of Medicine @mskdeptofmed.bsky.social · 19/06/2026

New study alert: Roni Shouval & team evaluated the frequency of second primary malignant neoplasms among those with #Lymphoma or #Myeloma who received T-cell–engaging bispecific antibodies. @mskcancercenter.bsky.social Read the study: bit.ly/4vYu0yL

022

MSK Department of Medicine @mskdeptofmed.bsky.social · 16/06/2026

A study led by @fungalspore.bsky.social found that higher levels of bacteria-derived valeric acid were associated with reduced Candida parapsilosis colonization in patients undergoing hematopoietic cell transplant, suggesting a potential strategy for preventing candidemia. bit.ly/3SI8ShD

011

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 02/06/2026

Closing out strong, join MSK radiation oncologist Dr. Amy Xu at #ASCO26 as she presents results from a phase II study evaluating genomically personalized radiation dose de-escalation in patients with pathogenic ATM mutations. 🕒 Tuesday, June 2 | 10:39 a.m. CDT Learn more: bit.ly/4x1m1ST

021

MSK Department of Medicine @mskdeptofmed.bsky.social · 01/06/2026

Coming up at #ASCO26: Join #melanoma medical oncologist Dr. Alexander Shoushtari for a presentation on how new tumor-infiltrating lymphocyte research can be translated into real benefit for patients. @mskcancercenter.bsky.social 🕒 Monday, June 1 | 5:30 p.m. CDT Learn more: bit.ly/4nX5jjg

011

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 01/06/2026

Join MSK's Dr. Michael Morris at #ASCO26 as he presents results from CONVERGE-01 Part 3 evaluating Ac-225 rosopatamab tetraxetan in patients w/ metastatic castration-resistant #prostatecancer previously treated with Lu-PSMA therapy. Learn more: meetings.asco.org/meetings/202...

011

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 01/06/2026

“By combining dual immunotherapy with TACE, we give patients a better chance of living longer while preserving a healthy, working liver.” Learn more: www.mskcc.org/news/liver-c...

111

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 01/06/2026

🚨 New findings presented at #ASCO26: An international phase 3 clinical trial led by MSK's Dr. Ghassan K. Abou-Alfa found that adding dual immunotherapy to TACE significantly increased progression-free survival for people with hepatocellular carcinoma (HCC).

111

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 01/06/2026

Join MSK medical oncologist Dr. Darren Feldman at #ASCO26 for an education session on optimizing treatment for patients with poor-risk testicular cancer, including a discussion on the management of brain metastasis. 🕒 Monday, June 1 | 1:51 p.m. CDT Learn more: bit.ly/4uEc3VN

042

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 01/06/2026

Join MSK thoracic medical oncologist Dr. Jamie Chaft at #ASCO26 as she presents results from the phase III ALCHEMIST trial evaluating nivolumab after surgery and adjuvant chemotherapy in patients with non-small cell lung cancer. 🕒 Monday, June 1 | 1:15 p.m. CDT Learn more: bit.ly/3Q9i1Pw

032

Reposted by MSK Department of Medicine

Aaron Mitchell @thewonkologist.bsky.social · 01/06/2026

Presenting our new study at #ASCO26 right now! Provider profits on cancer drugs have grown 4-fold to $40 billion in the last decade and a half. @ascocancer.bsky.social @mskcancercenter.bsky.social @hannahrabrams.bsky.social @nihcm.bsky.social

093

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 01/06/2026

Join MSK radiation oncologist Dr. Luke Pike at #ASCO26 as he presents research on a machine learning-driven model designed to help predict brain metastasis risk in patients with breast cancer. 🕒 Monday, June 1 | 9:57 a.m. CDT Learn more: bit.ly/4fnVLfb

021

Reposted by MSK Department of Medicine

Aaron Mitchell @thewonkologist.bsky.social · 01/06/2026

Presenting at #ASCO26 now! Our new study: Bribes from the drug industry can lead oncologists to use WORSE treatments (not just better ones) @ascocancer.bsky.social @mskcancercenter.bsky.social @dusetzinas.bsky.social @commonwealthfund.org @nihcm.bsky.social @arnoldventures.bsky.social

265

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 01/06/2026

Join MSK sarcoma medical oncologist Dr. Mark Dickson at #ASCO26 as he participates as an expert in a case-based panel discussion on consensus and controversies in well-differentiated/dedifferentiated retroperitoneal liposarcoma. 🕒 Monday, June 1 | 11:30 a.m. CDT Learn more: bit.ly/4ojpetb

021

MSK Department of Medicine @mskdeptofmed.bsky.social · 01/06/2026

Join MSK thoracic medical oncologist Dr. Kathryn Arbour at #ASCO26 as she presents an overview of the latest advances in targeting #KRAS G12-mutant cancers. Not to be missed! @mskcancercenter.bsky.social @kcarbourmd.bsky.social 🕒 Monday, June 1 | 10:36 a.m. CDT Learn more: bit.ly/3RHEfZl

This image is a promotional graphic for a medical presentation called 'Kracking KRAS G12D' on Monday, June 1, 10:30 a.m. CDT." The speaker is Kathryn Arbour, MD, a thoracic medical oncologist.

011

Reposted by MSK Department of Medicine

Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social · 01/06/2026

Join MSK gastrointestinal medical oncologist Dr. Ghassan Abou-Alfa at #ASCO26 as he presents efficacy and safety results from the phase 3 EMERALD-3 study. 🕒 Monday, June 1 | 9:45 a.m. CDT Learn more: bit.ly/4ecVY3A

011

MSK Department of Medicine @mskdeptofmed.bsky.social · 01/06/2026

Starting soon at #ASCO26: Dr. Ying Liu will present a poster on the NRG-GY036 trial comparing one vs. two years of maintenance olaparib (±bevacizumab) in #BRCA-mutated or HRD+ #OvarianCancer. @mskcancercenter.bsky.social 🕒 Monday, June 1 | 9 a.m. CDT Learn more: bit.ly/49zWDcJ

This image is a promotional graphic for an ASCO 2026 poster highlighting a phase trial of olaparib with or without bevacizumab for BRCA 1/2‑mutated ovarian cancer. Details include the speaker’s name and credentials, date (Monday, June 1), and time (9 a.m. CDT).

021

Reposted by MSK Department of Medicine

OncLive @onclive.bsky.social · 01/06/2026

WATCH: Alan L. Ho, MD, PhD, discusses the rationale for evaluating a ROR2-targeting antibody-drug conjugate in oropharyngeal squamous cell carcinoma. @mskcancercenter.bsky.social #hncsm #oncology See our head and neck cancers page for more insights! www.onclive.com/clinical/hea...

022